A reviewer of last year's linkurl:meta-analysis;http://content.nejm.org/cgi/content/abstract/356/24/2457 of GlaxoSmithKline's diabetes drug, linkurl:Avandia,;http://www.the-scientist.com/blog/display/53284/ leaked the study to the company prior to its publication in the __New England Journal of Medicine__, according to a linkurl:story;http://www.nature.com/news/2008/080130/full/451509a.html appearing today (Jan. 30) in __Nature__. Last year, Avandia, joined the ranks of blockbuster drugs associated with serious health risks: The meta-analysis published in __NEJM__ showed that the Avandia increased the risk of heart attacks in patients who took it. It turns out that Steven Haffner, a diabetes researcher at the University of Texas Health Science Center at San Antonio, faxed a copy of the manuscript to GSK more than two weeks prior to its publication in __NEJM__. Haffner admitted to __Nature__ that he leaked the study, but failed to divulge a motive for his actions. "Why I sent it is a mystery," Haffner told the journal. "I don't really understand it. I wasn't feeling well. It was...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!